Abstract:
Introduction: Tuberculosis is a bacterial infection, endemic and contagious disease, caused by
Mycobacterium tuberculosis, which affects, according to statistics of the World Health Organization
year 2014, 9.6 million of population, including new cases of illness 6 million and 480 thousands
multidrug-resistant TB. The studies of TB drugs in our country and from the world, have demonstrate
that the efficiency of treatment is increasingly smaller. So, our goal is the formulation of capsules with
propiltiodiazolochinazolin-one, a new original compound antimycobacterial.
Materials and methods:We studed the bibliographic advanced nomenclature of excipients used
most often in solid formulations with antimycobacterial therapeutic effect, depending on the structure of
active substances and physico-chemical properties. We selected the following auxiliary substances:
anhydrous lactose, lactose monohydrate, magnesium stearate, microcrystalline cellulose,
polyvinylpyrrolidone, sodium starch gluconate, polyethyleneglycol 4000, 6000.
Results and discussion: Propiltiodiazolochinazolin-one is a microcrystalline substance,
insoluble in water, which allow us to choose excipients which can be used in gels, to obtain granules
and excipients with a certain concentration of water, to obtain powders. In the base of the list of selected
excipients, were elaborate six formulation of capsules, for which subsequently will be determinated the
physico-chemical and technology properties of powders and granulates.
Conclusion: The selected excipients, according to the physico-chemical characteristics, the
structure and the therapeutic effects of the active substance, allow the formulation of the
antimycobacterial capsules with propiltiodiazolochinazolin-one.
Description:
Faculty of Pharmacy, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova, The 6th International Medical Congress for Students and Young Doctors, May 12-14, 2016
